1.23
+0.15(+13.89%)
Currency In USD
| Previous Close | 1.08 |
| Open | 1.11 |
| Day High | 1.24 |
| Day Low | 1.06 |
| 52-Week High | 7.5 |
| 52-Week Low | 0.62 |
| Volume | 774,315 |
| Average Volume | 439,598 |
| Market Cap | 22.7M |
| PE | -0.38 |
| EPS | -3.25 |
| Moving Average 50 Days | 1 |
| Moving Average 200 Days | 2.09 |
| Change | 0.15 |
If you invested $1000 in BioVie Inc. (BIVI) since IPO date, it would be worth $12.31 as of May 09, 2025 at a share price of $1.23. Whereas If you bought $1000 worth of BioVie Inc. (BIVI) shares 3 years ago, it would be worth $40.33 as of May 09, 2025 at a share price of $1.23.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson’s Disease and Related Disorders (IAPRD 2025)
GlobeNewswire Inc.
May 07, 2025 12:00 PM GMT
CARSON CITY, Nev., May 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced
BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth
GlobeNewswire Inc.
May 05, 2025 12:00 PM GMT
The seven-member Board includes Cedars-Sinai brain health leader Dr. Zaldy Tan, Parkwood marketing powerhouse Justina Omokhua, and Neuralink visionary Tim Gardner Each Board member brings deep personal conviction and cross-sector expertise to unlock
BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient Enrolled
GlobeNewswire Inc.
Apr 16, 2025 12:00 PM GMT
SUNRISE-PD evaluating the Company’s anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson’s disease who have not been treated with carbidopa/levodopa SUNRISE-PD is one of very few clinical trials for a Parkinson’s dis